Geron Corp (GERN) Q4 2025 Earnings Call Transcript

Why It Matters

The guidance signals Geron’s transition from launch to scalable growth, positioning Rytelo as a key second‑line therapy in a sizable MDS market while maintaining strong liquidity for continued investment.

Key Takeaways

• Rytelo 2025 revenue $184M, Q4 $48M.
• 2026 revenue guidance $220‑240M, operating expenses $230‑240M.
• Gross‑to‑net deductions rise to 17.7% in 2025.
• Prescribing accounts reach ~1,300, 150 new Q4.
• Targeting 8,000 second‑line lower‑risk MDS patients in U.S.

Pulse Analysis

Geron’s 2025 earnings underscore the commercial momentum of Rytelo, its telomerase inhibitor for lower‑risk myelodysplastic syndromes. Achieving $184 million in net revenue during its first full year of availability reflects both successful market entry and growing prescriber confidence. The company’s disciplined expense management—cutting R&D spend and modestly reducing SG&A—creates a healthier cost structure, while a robust cash position and access to additional debt provide flexibility for strategic initiatives.

The firm’s forward‑looking strategy centers on deepening penetration within the second‑line MDS segment, estimated at roughly 8,000 eligible patients in the United States. By targeting high‑volume community practices and leveraging a multi‑channel “surround sound” marketing approach, Geron aims to accelerate demand growth, as evidenced by a 9% quarter‑over‑quarter increase and a 13% rise in prescribing accounts. The expansion of investigator‑sponsored trials and real‑world evidence studies further strengthens Rytelo’s clinical narrative, positioning it favorably against competitors and aligning with NCCN guideline recommendations.

Financially, the projected 2026 revenue range of $220‑$240 million, coupled with operating expenses trimmed to $230‑$240 million, suggests an improving path toward profitability, even though management emphasizes reinvestment over short‑term breakeven. Rising gross‑to‑net deductions to 17.7% highlight the impact of broader 340B and GPO participation, a trend likely to persist as the drug gains market share. Meanwhile, the upcoming interim analysis of the IMPACT MF trial could unlock additional indications, adding upside potential to Geron’s growth trajectory and reinforcing its position as a hematology specialty player.